BioCardia, Inc. (BCDA) Stock
Healthcare · Biotechnology · Member of Other US Stocks
BioCardia, Inc. (BCDA) closed at USD 0.94 on 2026-10-15, a change of -28.2 % over the past year, with a market capitalization of USD 13.93M.
BioCardia, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-15 | 0.94 |
| 2026-10-14 | 0.93 |
| 2026-10-13 | 0.99 |
| 2026-10-12 | 1.02 |
| 2026-10-09 | 1.04 |
| 2026-10-08 | 1.06 |
| 2026-10-07 | 1.09 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
BioCardia, Inc. key figures
- Previous close
- USD 0.94 (2026-10-15)
- 1-year change
- -28.2 %
- Market cap
- USD 13.93M
- Enterprise value
- USD 10.11M
- P/E ratio (trailing)
- -1.44
- P/E ratio (forward)
- -1.59
- EPS (trailing)
- -0.64
- EPS (forward)
- -0.58
- PEG ratio
- n/a
- Price to book
- 5.11
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 1.83
- Employees
- 17
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for BioCardia, Inc. and compare it with other stocks.
Analyze BCDAAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell BioCardia, Inc. shares.